Pa aroxysmal supraventricular tachycardia (PSVT)
is a common clinical problem. Despite many advances in our knowledge of its mechanisms, proving that antiarrhythmic therapy reduces the incidence of spontaneous PSVT events has been difficult. PSVT is known to degenerate into atrial fibrillation."1 Paroxysmal atrial fibrillation occurred in only two patients in the randomized phase. In both of these patients, symptomatic paroxysmal atrial fibrillation and symptomatic PSVT events were documented. Also, of three others in whom paroxysmal atrial fibrillation events were recorded in the screening phase, only one continued in the randomized phase. Thus, our decision to handle symptomatic atrial fibrillation in this manner did not affect the results of the study. Symptomatic nonelectrocardiographically documented palpitations were not considered events.
To assure safety throughout the trial, prospective 12-lead electrocardiographic recordings and analyses were obtained (prestudy, end of dose ranging, crossover, and at the end of the study). Also, hematologic parameters, biochemical parameters, and urinalyses were examined (prestudy, at crossover, and at the end of the study).
An optional electrophysiological study could be performed before the dose-ranging phase to assess the mechanism of PSVT and the electrophysiological effects of intravenous flecainide. The results of the electrophysiological study involving intravenous flecainide were intended not to influence the patient's entry into the dose-ranging or efficacy phases of the study.
Statistical Analysis
The effect of flecainide compared with placebo on the occurrence of symptomatic PSVT events was analyzed according to the following parameters: number of patients having no events, time to first event, interval between events, and ventricular rate during PSVT. Data from all centers were combined in the analyses. McNemar's test for significant change was used to compare the number of patients with no symptomatic PSVT events for placebo and flecainide.12 When determining the time to first event and the interval between events, the first 3 days of each 8-week treatment period were excluded in deference to flecainide's steady-state pharmacokinetics; day 4 of each period was defined as the first treatment day.6 Time to first attack was defined as the number of treatment days until the first attack. If a patient did not have any symptomatic events during the treatment, time to first event was defined as the number of treatment days plus one, and the measurement was censored at that time.
For patients with one to four events, the interval between events was defined as the number of days on treatment divided by the number of events. According to protocol, a treatment period ended after four events or 8 weeks, whichever came first. However, some patients had more than four events before crossing over to the next treatment. When determining the interval between attacks, only the first four events were used. If a patient did not have any events on treatment, the interval was defined to be the number of treatment days plus one and was considered a censored observation.
The data are presented in means, standard errors of the mean, and medians using the Kaplan-Meier (Figure 2 ) and were analyzed.
Of the 17 patients who did not complete the study, six withdrew for personal reasons, and three were discontinued after adverse cardiac events. Two of these three events occurred during electrophysiological testing: one patient had incessant PSVT after intravenous flecainide administration, and one patient had ventricular fibrillation induced during programmed ventricular stimulation after intravenous flecainide administration; neither of these patients received oral flecainide. The third patient had a documented myocardial infarction and was subsequently found angiographically to have normal coronary arteries. Three patients were discontinued from study because of noncardiac adverse experiences, two for protocol violations, one because the patient believed the drug was ineffective, and two because of noncompliance (lost to follow-up).
Characteristics of the analyzed patients and nonanalyzed patients are enumerated in Table 1 Table 2 ). As indicated in Table 2 Figure 3 shows the time to first symptomatic PSVT event during the flecainide and the placebo randomized treatment periods for the 34 patients. During flecainide treatment, the cumulative proportion of patients remaining free of tachycardia for 8 weeks was 0.79 compared with 0.15 for placebo treatment (p<0.001) (Figure 3 ). In addition ( Figure 4 ).
Side Effects of Flecainide Therapy During Efficacy Phase
Nuisance side effects during active treatment not requiring discontinuation or change in dosage were greater on flecainide therapy than placebo (Table 4) . On flecainide therapy, 37% of the patients reported no side effects compared with 64% on placebo (p<O0.Q5). Visual abnormality was the only side effect that was statistically greater with flecainide (29%) than with placebo (8%) (p<0.05) (see Table 4 ).
Discussion
We found flecainide clearly to be efficacious in our study population, markedly decreasing symptomatic PSVT events during the 8-week active treatment period ( Figure 3 and Table 3 ). There were only eight events in the flecainide phase compared with 29 in the placebo phase. In addition, the median time to first PSVT event increased substantially (>55 days on flecainide compared with 11 days on placebo, p<O.OOl) as did the time between PSVT events (median number of days between attacks of 12 days on placebo and >55 days on flecainide, p<0.001). drawing from the study. Because this study was TIME IN DAYS UNTIL FIRST PSVT EVENT designed to determine whether flecainide was efficatE 3 There were no significant adverse experiences in patients in the randomized phase. Two of three adverse cardiac experiences occurred after intravenous flecainide administration. One was possibly a nonspecific induction of ventricular fibrillation by ventricular stimulation, but we classified it as an adverse experience. One patient had incessant PSVT after intravenous flecainide administration that resolved after discontinuation of intravenous flecainide. One patient had a myocardial infarction with normal coronary arteries, probably unrelated to flecainide therapy. Other adverse experiences were characteristic of flecainide as previously recognized (Table 4) .
During oral administration of flecainide in this protocol, none of the patients had serious ventricular arrhythmias or sudden cardiac arrest. However, 48 patients is a relatively small number on which to estimate the true incidence of uncommon events. When flecainide was being studied for treatment of ventricular arrhythmias, it was thought to exacerbate ventricular arrhythmias in a small, but important, fraction of patients, particularly those with poor ventricular function.17 Also, flecainide was associated with an increased arrhythmic death and total cardiovascular mortality compared with placebo among patients with premature ventricular beats after myocardial infarction treated in the Cardiac Arrhythmia Suppression Trial.18 None of our analyzed patients (Table 1 ) had a prior myocardial infarction, presumably making them a low-risk group for ventricular arrhythmic events. When making a decision to initiate drug therapy for the generally benign arrhythmia of PSVT, the striking efficacy of flecainide demonstrated in this study must be considered in light of the unknown (though presumably low) risk of serious proarrhythmic events in patients such as ours, without prior myocardial infarction or other significant structural heart disease.
Implications for Patient Therapy
Based on our study results, in a patient population without substantial structural heart disease, yet with significant prior exposure to agents such as digoxin, calcium channel antagonists, and ,8-blockers, flecainide appears safe and clearly efficacious for the prevention of symptomatic electrocardiographically documented PSVT. Flecainide should be considered an important therapeutic alternative for patients having PSVT. 
